EUVIMEDEUVIMED entdecken
Crossref

6‐Mercaptopurine potently inhibits recruitment of SHP2 by phosphorylated PD ‐1 to inhibit PD ‐1 signalling and enhance T cell function

Lu Liu iD, Yuxi Lei, Zongyao Zheng, Xingang Zhou, Shuzhen Chen, Guandi Zeng, Lei Yu, Peng Wang, Liang Chen iD

Immunology · 2023-10 · 170 (2) · 230-242

DOI: 10.1111/imm.13671 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunology, 2023-06. Verfasst von Lu Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: MOE Key Laboratory of Tumor Molecular Biology and Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes, Institute o…. Hauptthemen laut MEDLINE: Mercaptopurine, Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody inhibitors that block PD‐1/PD‐L1 interaction have been approved for oncological clinics, yielding impressive treatment effects. Small molecules inhibiting PD‐1 signalling are at various stages of development, given that small molecular drugs are expected to outperform protein drugs in several ways. Currently, a significant portion of these small molecular inhibitors achieve this purpose by binding to a limited region of the PD‐L1 protein, thereby limiting the choice of chemical structures. Alternative strategies for developing small‐molecular PD‐1 inhibitors are urgently needed to broaden the choice of chemical structures. Here, we report that 6‐mercaptopurine (6‐MP) inhibits PD‐1 signalling, activates T cell function in vitro and in vivo and shrinks tumours by activating cytotoxic T cells. Mechanistically, 6‐MP potently inhibited PD‐1 signalling by blocking the recruitment of SHP2 by PD‐1. Considering that 6‐MP is a chemotherapeutic agent already approved by the FDA for childhood leukaemia, our work revealed a novel anti‐tumour mechanism for this drug and suggests that 6‐MP warrants further clinical evaluation for other tumour types.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MercaptopurineNeoplasmsHumansChildProgrammed Cell Death 1 ReceptorSignal TransductionT-LymphocytesB7-H1 AntigenImmunotherapy

Stichwörter der Autor:innen

6-mercaptopurinePD-1 inhibitorimmunotherapyprotein-protein interactiontransgenic mouse model

Substanzen

MercaptopurineProgrammed Cell Death 1 ReceptorB7-H1 Antigen

Autor:innen und Institutionen

  • MOE Key Laboratory of Tumor Molecular Biology and Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes, Institute of Life and Health Engineering, College of Life Science and Technology,…
  • Department of Pathlogy & Laboratory Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Beijing Tongren Hospital, Capital Medical University, Beijing, China.

ORCID-Profile: Lu Liu, Liang Chen

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Liu, L., Lei, Y., Zheng, Z., Zhou, X., Chen, S., Zeng, G., Yu, L., Wang, P., & Chen, L. (2023). 6‐Mercaptopurine potently inhibits recruitment of SHP2 by phosphorylated PD ‐1 to inhibit PD ‐1 signalling and enhance T cell function. Immunology, 170(2), 230-242. https://doi.org/10.1111/imm.13671

Vancouver

Liu L, Lei Y, Zheng Z, Zhou X, Chen S, Zeng G, et al. 6‐Mercaptopurine potently inhibits recruitment of SHP2 by phosphorylated PD ‐1 to inhibit PD ‐1 signalling and enhance T cell function. Immunology. 2023;170(2):230-242. doi:10.1111/imm.13671

BibTeX
@article{Liu2023,
  author = {Liu, Lu and Lei, Yuxi and Zheng, Zongyao and Zhou, Xingang and Chen, Shuzhen and Zeng, Guandi and Yu, Lei and Wang, Peng and Chen, Liang},
  title = {6‐Mercaptopurine potently inhibits recruitment of SHP2 by phosphorylated PD ‐1 to inhibit PD ‐1 signalling and enhance T cell function},
  journal = {Immunology},
  year = {2023},
  volume = {170},
  number = {2},
  pages = {230--242},
  doi = {10.1111/imm.13671}
}
Kostenlos starten →